Comparison between Akme Fintrade IPO and Kronox Lab Sciences IPO.
Akme Fintrade IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Kronox Lab Sciences IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Akme Fintrade IPO is up to ₹132.00 Cr whereas the issue size of the Kronox Lab Sciences IPO is up to ₹130.15 Cr. The final issue price of Akme Fintrade IPO is ₹120.00 per share and of Kronox Lab Sciences IPO is ₹136.00 per share.
| Akme Fintrade IPO | Kronox Lab Sciences IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹114.00 per share | ₹129.00 per share |
| Issue Price (Upper) | ₹120.00 per share | ₹136.00 per share |
| Issue Price (Final) | ₹120.00 per share | ₹136.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 125 shares | 110 shares |
| Fresh Issue Size | 1,10,00,000 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹132.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 95,70,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹130.15 Cr |
| Issue Size Total | 1,10,00,000 shares | 95,70,000 shares |
| Issue Size Total (Amount) | up to ₹132.00 Cr | up to ₹130.15 Cr |
Akme Fintrade IPO opens on Jun 19, 2024, while Kronox Lab Sciences IPO opens on Jun 03, 2024. The closing date of Akme Fintrade IPO and Kronox Lab Sciences IPO is Jun 21, 2024, and Jun 05, 2024, respectively.
| Akme Fintrade IPO | Kronox Lab Sciences IPO | |
|---|---|---|
| Anchor Bid Date | Jun 18, 2024 | May 31, 2024 |
| Issue Open | Jun 19, 2024 | Jun 03, 2024 |
| Issue Close | Jun 21, 2024 | Jun 05, 2024 |
| Basis Of Allotment (Tentative) | Jun 24, 2024 | Jun 06, 2024 |
| Initiation of Refunds (Tentative) | Jun 25, 2024 | Jun 07, 2024 |
| Credit of Share (Tentative) | Jun 25, 2024 | Jun 07, 2024 |
| Listing date (Tentative) | Jun 26, 2024 | Jun 10, 2024 |
| Anchor Lockin End date 1 | Jul 24, 2024 | Jul 06, 2024 |
| Anchor Lockin End date 2 | Sep 22, 2024 | Sep 04, 2024 |
Akme Fintrade IPO P/E ratio is , as compared to Kronox Lab Sciences IPO P/E ratio of 30.37.
| Akme Fintrade IPO | Kronox Lab Sciences IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 56.01 | 99.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 74.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 30.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹504.61 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 5.64% | 25.66% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 33.15% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.49 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹3.87 | ₹4.48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 5.81% | 25.66% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Akme Fintrade IPO Retail Individual Investors (RII) are offered 36,57,500 shares while in Kronox Lab Sciences IPO retail investors are offered 36,57,500 shares. Qualified Institutional Buyers (QIB) are offered 20,90,000 shares in Akme Fintrade IPO and 19,14,000 shares in Kronox Lab Sciences IPO.
| Akme Fintrade IPO | Kronox Lab Sciences IPO | |
|---|---|---|
| Anchor Investor Reservation | 31,35,000 shares | 28,71,000 shares |
| Market Maker Reservation | ||
| QIB | 20,90,000 shares | 19,14,000 shares |
| NII | 15,67,500 shares | 14,35,500 shares |
| RII | 36,57,500 shares | 33,49,500 shares |
| Employee | 5,50,000 shares | |
| Others | ||
| Total | 1,10,00,000 shares | 95,70,000 shares |
Akme Fintrade IPO subscribed 54.49x in total, whereas Kronox Lab Sciences IPO subscribed 117.25x.
| Akme Fintrade IPO | Kronox Lab Sciences IPO | |
|---|---|---|
| QIB (times) | 28.12x | 89.03x |
| NII (times) | 129.98x | 301.92x |
| Big NII (times) | 121.56x | 322.26x |
| Small NII (times) | 146.83x | 261.22x |
| RII (times) | 44.58x | 54.24x |
| Employee (times) | 5.42x | |
| Other (times) | ||
| Total (times) | 54.49x | 117.25x |
